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1. Introduction
Since that the smallpox vaccine became available in the late eighteenth century, a significant 
number of diseases were gradually being controlled by vaccines, which are currently consid-
ered the most successful and cost-effective intervention in public health [1]. Recent data from 
Gavi - the Vaccine Alliance [2] in a survey for 10 immunopreventable diseases in 41 develop-
ing countries, indicate vaccines will prevent 36 million deaths between 2016 and 2030. The 
impact of vaccination extends from “saving lives” to socioeconomic aspects, in a line of cause 
and effect between health and social productivity. After almost 70 years, vaccination around 
the world ended up exerting selective pressure in the microbial environment, so it is now 
virtually impossible to know how it would be like if the vaccines had not been introduced.
However, the control of microorganisms by the vaccines may lead the population to the false 
impression that pathogens responsible for devastating epidemics in the past centuries are 
definitively extinguished. As a consequence, the refusal of vaccines, for religious or philo-
sophical questions, or even for discredit on the effectiveness and safety of these products is 
becoming a growing concern. This change in population behavior, fueled by the relatively 
recent technology allowing for almost instantaneous dissemination of information, whether 
true or false, has been observed in several countries, with a consequent increase in the number 
of cases and deaths related to infections that can be controlled by vaccines, as has been hap-
pening in relation to measles and whooping cough, in a very worrying way.
In this book, we propose some approaches about interrelationships between vaccine strategies 
and microbial epidemiology, taking as reference the whooping cough, an endemic disease 
with significant morbidity and mortality and of indisputable importance in public health.
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The major causative agent of pertussis, Bordetella pertussis, was first isolated in 1906 by Bordet 
and Gengou [3], and throughout that century, endemic and epidemic episodes of the disease 
were recorded [4].
In 1933, a vaccine which conferred a certain degree of protection was described, a suspension 
of killed B. pertussis cells [5]. In that decade and in the next, several whole cell pertussis prepa-
rations have been described and used in both prevention and treatment of the disease, with 
some efficacy [6]. In 1947, the Kendrick protection test was described, with intracerebral chal-
lenge in mice that is until now recommended by the WHO as an assay of potency of whole cell 
pertussis vaccines and the only one that showed correlation with protection in children [7]. 
Immunization against pertussis is part of the childhood immunization schedule and in some 
countries it is also recommended in booster doses for adolescents and adults [8]. Whole cell 
pertussis vaccines (wP), composed of inactivated suspensions of partially detoxified B. pertus-
sis, have been used in vaccination programs for 60 years with proven efficacy, combined with 
tetanus and diphtheria toxoids adsorbed on aluminum salts as adjuvants [9]. The introduc-
tion of these vaccines in the 1950s–1960s led to a dramatic reduction of more than 90% in the 
incidence and mortality caused by the disease in the industrialized world [10].
Adverse reactions related to them led to development of acellular pertussis vaccines (aP), con-
taining purified antigenic components of B. pertussis. These preparations are effective and less 
reactogenic [11], and they have replaced the (wP) in several countries in the last two decades. 
However, their cost of production is much higher, making prohibitive their introduction in 
developing countries. Preliminary clinical trials in the 1990s comparing bacterial triple vac-
cines formulated with diphtheria (D) and tetanus (T) toxoids combined with whole cell per-
tussis component (DTwP) or acellular pertussis component (DTaP), suggested similar efficacy 
and immunogenicity [12–16]. More recent data showed that pertussis is not adequately con-
trolled, and epidemic outbreaks are occurring even in countries with high vaccination cover-
age, making the resurgence of the disease a worldwide problem [17–19].
This increase in the incidence is certainly related to multiple factors. The improved diagnostic 
testing, which would lead to an increase in reported cases; the decrease in vaccine efficacy and 
faster loss of immunity could certainly contribute to this scenario [20].
Besides that, the introduction of the aP vaccines which appear to require earlier and more 
frequent booster doses for disease control, suggest a shorter period of effective immunity [21]. 
A recent study in a systematic review and meta-analysis of published studies comparing the 
efficacy of wP and aP within 3 years after the 3-dose primary series concluded that the protec-
tion against the disease was lower for aP vaccines than for the wP, with efficacy of 84% and 
94%, respectively [22]. The study, comparing the duration of immunity conferred by child-
hood vaccination scheme using 3–5 doses of DTaP, suggested that for each year after the last 
dose of DTaP, the disease probability would be increased 1.33 times. Assuming 85% of vaccine 
efficacy it was estimated that only 10% of the vaccinated children had persistence of pertussis 
immunity for a period of 8.5 years after the last dose [22].
Broadly speaking, aP vaccines are considered safer, but there is a currently consensus that they 
also require more frequent booster doses, given that they confer protective immunity for a shorter 
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period than that elicited by wP, besides not preventing colonization and transmission after chal-
lenge [23]. Recent WHO reports confirm that wP and aP are equivalent in disease prevention in 
the first year of life, but that there is in fact a more rapid loss of immunity conferred by aPs [24].
In this sense, alternative pertussis vaccines have been suggested, including a live attenuated 
pertussis vaccine [25] and a whole cell pertussis vaccine with reduced content of endotoxin [26]. 
Although with efficient and safe alternatives for prevention, pertussis is still the most frequent 
and lethal immunopreventable disease. New vaccine options, combined with strategic actions 
in immunization programs, are still essential for disease control and the spread of the micro-
organism in the target populations.
The following chapters will focus on different aspects of the pertussis host-pathogen inter-
relationship. Important epidemiological aspects that may contribute to the diagnosis of the 
microorganism and treatment of the disease will be addressed. Current vaccine proposals, the 
current disease control situation and future challenges will be discussed. In this sense, it will 
be approached the modern vaccination strategies that aim to focus children under one year of 
age, mainly on the group up to 6 months, still with incomplete vaccination schedule, acquir-
ing the infection from adults and adolescents of their conviviality. Vaccination of the mother 
during pregnancy a strategy that has been successfully adopted for the protection of the new-
born; the currently used vaccines and the influence of high vaccination coverage strategies in 
the incidence of the disease should be also discussed.
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